EPS: As of FY2025 Q2, the actual value is USD -5.46.<h3>Segment Revenue</h3><ul><li>Research and Development Expenses: $1.8 million for the three months ended June 30, 2025, compared to $25,000 for the same period in 2024. For the six months ended June 30, 2025, expenses were $2.8 million, compared to $153,000 for the same period in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: $6.0 million for the three months ended June 30, 2025, compared to $5.4 million for the same period in 2024. For the six months ended June 30, 2025, net loss was $10.8 million, compared to $8.9 million for the same period in 2024.</li><li>General and Administrative Expenses: $3.1 million for the three months ended June 30, 2025, compared to $3.1 million for the same period in 2024. For the six months ended June 30, 2025, expenses were $5.8 million, compared to $5.9 million for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: Net cash used in operating activities was $6.5 million for the six months ended June 30, 2025, compared to $3.9 million for the same period in 2024.</li><li>Investing Cash Flow: Net cash used in investing activities was $405,000 for the six months ended June 30, 2025, compared to $224,000 for the same period in 2024.</li><li>Financing Cash Flow: Net cash provided by financing activities was $9.7 million for the six months ended June 30, 2025, compared to $113,000 for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Convertible Notes Payable: As of June 30, 2025, there was approximately $3.6 million in outstanding principal and interest remaining on the A.G.P. Convertible Note.</li><li>Warrants: The Company issued 1,908 A.G.P. 2024 Warrants to purchase shares of Common Stock at an exercise price of $157.20 per share.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: CDT Equity Inc. plans to continue leveraging artificial intelligence and solid-form chemistry to enhance and advance high-potential therapeutic assets. The company aims to unlock the value of clinical-stage compounds, particularly those deprioritized by larger pharmaceutical companies, and extend patent life by up to 20 years through advanced co-crystallization and solid-form technologies.</li><li>Non-Core Business: The company is exploring a cryptocurrency treasury reserve strategy as part of a diversified capital management approach. This strategy aims to present both strategic and financial benefits by gaining long-term exposure to digital assets.</li><li>Priority: CDT Equity Inc. will focus on high-leverage development strategies, avoiding the cost burden of late-stage clinical trials, and will seek third-party license deals following successful pre-clinical trials.</li></ul>

CONDUIT PHARMACEUTICALS INC C/WTS 22/09/2028(TO PUR COM) | 10-Q: FY2025 Q2 EPS: USD -5.46